Arca
Skip to content
Tools
Tools

F3: Tissue factor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Initiates blood coagulation by forming a complex with circulating factor VII or VIIa.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on F3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody-drug conjugate

Approved1

  • Tisotumab vedotin

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionMechanismOpen trialsWarnings
        Tisotumab vedotinApprovedPfizerAntibody-drug conjugateBinding agentCoagulation factor III binding agent4Boxed warning

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
        Tisotumab Vedotin in Squamous Cell Carcinoma of the VulvaTisotumab vedotinPhase 2Not yet recruitingGOG Foundation2026-06-29
        Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerTisotumab vedotinPhase 4RecruitingPfizer2025-05-01
        A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Tisotumab vedotinPhase 3Active, not recruitingMerck Sharp & Dohme LLC2024-06-14
        Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsTisotumab vedotinPhase 2Active, not recruitingSeagen, a wholly owned subsidiary of Pfizer2018-04-02

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Cancer
        0.38
        Neoplasm
        0.38
        Spontaneous coronary artery dissection
        0.26
        Placental abruption
        0.26
        Head and neck squamous cell carcinoma
        0.07
        Non-small cell squamous lung carcinoma
        0.07

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4081, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P13726, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.